SINICCO, Alessandro
SINICCO, Alessandro
Dip. DISCIPLINE MEDICO CHIRURGICHE (attivo dal 01/01/1900 al 30/04/2013)
An outbreak of HIV-1 subtype G among Italian injecting drug users.
2007-01-01 CICCOZZI M; MONTIERI S; SALEMI M; DE OLIVEIRA T; DORRUCCI M; A. SINICCO; DE LUCA A; GIULIANI M; BALOTTA C; REZZA G
Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus
2007-01-01 AGUILAR MARUCCO D; VERONESE L; DE REQUENA DG; BONORA S; CALCAGNO A; CAVECCHIA I; SINICCO A; DE ROSA FG; CARITI G; DI PERRI G
Asymptomatic women at high risk of vertical HIV-1 transmission to their fetuses.
1993-01-01 TIBALDI C; TOVO PA; ZIARATI N; PALOMBA E; SALASSA B; SCIANDRA M; D'AMBROSIO R; PONTI A; SINICCO A
Clearance of 14-3-3 protein from cerebrospinal fluid heralds the resolution of bacterial meningitis.
2003-01-01 BONORA S; ZANUSSO G; RAITERI R; MONACO S; ROSSATI A; FERRARI S; BOFFITO M; AUDAGNOTTO S; SINICCO A; RIZZUTO N; CONCIA E; DI PERRI G
Clinical pharmacology of antiretroviral therapy
2004-01-01 DI PERRI G; SINICCO A; AUDAGNOTTO S; GOBBI F; CANTA F; MARRONE R; BONORA S
Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics.
2002-01-01 BOFFITO M ;ARNAUDO I ;RAITERI R ;BONORA S ;SINICCO A ;DI GARBO A ;REYNOLDS HE ;HOGGARD PG ;BACK DJ ;DI PERRI G
Cut-off values of ribavirin trough concentration for sustained virological response and for hematological toxicity in HCV/HIV-co-infected patients treated with RBV and Pegylated Interferon
2007-01-01 Aguilar Marucco D; Gonzalez de Requena D; Veronese L; Bonora S; Ibanez A; Baietto L; D'Avolio A; Sciandra M; Sinicco A; Di Perri G
Cytokine network and acute primary HIV-1 infection.
1993-01-01 SINICCO A ;BIGLINO A ;SCIANDRA M ;FORNO B ;POLLONO AM ;RAITERI R ;GIOANNINI P
Detection of stavudine concentrations in plasma of HIV-infected patients taking zidovudine
2004-01-01 BONORA S; BOFFITO M; D'AVOLIO A; SCIANDRA M; CACI AM; CONTA F; SINICCO A; DE ROSA FG; DI PERRI G
EFFETTO DI LOPINAVIR/RITONAVIR SULLE CONCENTRAZIONI PLASMATICHE DI TRIGLICERIDI E COLESTEROLO: VALUTAZIONE FARMACOCINETICA
2002-01-01 Boffito M.; Bonora S.; Raiteri R.; Sinicco A.; Sciandra M.; D'Avolio A.; Sales P.; Trentini L.; Sciolè K.; Caci A.M.; Di Perri G.
FARMACOCINETICA DEI FARMACI ANTIRETROVIRALI NELLA PRATICA CLINICA
2002-01-01 Boffito M.; Bonora S.; Raiteri R.; Sinicco A.; Sciandra M.; D'Avolio A.; Hoggard P.G.; Back D.J.; Di Perri G.
GREATER IMMUNOLOGICAL RECOVERY ASSOCIATED WITH ADDITIONAL ENFUVIRTIDE IN THE TREATMENT OF NAIVE HIV-INFECTED PATIENTS AT VERY ADVANCED DISEASE STAGES: 24-WEEK RESULTS OF A RANDOMIZED, CONTROLLED, PILOT STUDY
2009-01-01 Calcagno A.; Bonora S.; Cometto C.; Fontana S.; Aguilar D.; D'Avolio A.; de Requena D. Gonzalez; Maiello A.; Sinicco A.; Di Perri G
Immunoglobulin and Myc gene structure in lymphnode biopsies from HIV-positive patients with LAS and lymphoma.
1990-01-01 SAGLIO G ;FOÁ R ;GUERRASIO A ;DI CELLE PF ;PALESTRO G ;SINICCO A ;GOBBI M ;GAVOSTO F
Impact of nevirapine (NVP) trough concentrations (Ctrough) on time to achieve and time maintenance of viral suppression (VS) in HIV+ patients taking NVP-based regimens
2004-01-01 Bonora S.; Requena D.; Garazzino S.; Sciandra M.; D'Avolio A.; Raiteri R.; Canta F.; Marrone R.; Boffito M.; Caci A.; Sinicco A.; Di Perri G.
Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring.
2003-01-01 BOFFITO M; BACK DJ; HOGGARD PG; CACI A; S. BONORA; RAITERI R; SINICCO A; REYNOLDS HE; KHOO S; DI PERRI G
Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boosting.
2003-01-01 BOFFITO M; BONORA S; SALES P; DAL CONTE I; SINICCO A; HOGGARD PG; KHOO S; BACK DJ; DI PERRI G
Longitudinal analysis of the 90K glycoprotein in the Italian HIV-seroconversion study: temporal trend and predictability of the maturity of HIV infection.
2004-01-01 DORRUCCI M ;IACOBELLI S ;SULIGOI B ;PEZZOTTI P ;SINICCO A ;ANGARANO G ;TINARI N ;REZZA G
Lopinavir protein binding in vivo through the 12-hour dosing interval
2004-01-01 BOFFITO M; HOGGARD PG; LINDUP WE; BONORA S; SINICCO A; KHOO SH; DI PERRI G; BACK DJ
Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting
2005-01-01 GONZÁLEZ DE REQUENA D; BONORA S; GARAZZINO S; SCIANDRA M; D'AVOLIO A; RAITERI R; MARRONE R; BOFFITO M; DE ROSA FG; SINICCO A; DI PERRI G
Oral lesions in children born to HIV-1 positive women.
1993-01-01 MONIACI D; CAVALLARI M; GRECO D; BRUATTO M; RAITERI R; PALOMBA E; TOVO PA; SINICCO A
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| An outbreak of HIV-1 subtype G among Italian injecting drug users. | 2007 | CICCOZZI M; MONTIERI S; SALEMI M; DE OLIVEIRA T; DORRUCCI M; A. SINICCO; DE LUCA A; GIULIANI M; BALOTTA C; REZZA G | |
| Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus | 2007 | AGUILAR MARUCCO D; VERONESE L; DE REQUENA DG; BONORA S; CALCAGNO A; CAVECCHIA I; SINICCO A; DE ROSA FG; CARITI G; DI PERRI G | |
| Asymptomatic women at high risk of vertical HIV-1 transmission to their fetuses. | 1993 | TIBALDI C; TOVO PA; ZIARATI N; PALOMBA E; SALASSA B; SCIANDRA M; D'AMBROSIO R; PONTI A; SINICCO A | |
| Clearance of 14-3-3 protein from cerebrospinal fluid heralds the resolution of bacterial meningitis. | 2003 | BONORA S; ZANUSSO G; RAITERI R; MONACO S; ROSSATI A; FERRARI S; BOFFITO M; AUDAGNOTTO S; SINICCO A; RIZZUTO N; CONCIA E; DI PERRI G | |
| Clinical pharmacology of antiretroviral therapy | 2004 | DI PERRI G; SINICCO A; AUDAGNOTTO S; GOBBI F; CANTA F; MARRONE R; BONORA S | |
| Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. | 2002 | BOFFITO M ;ARNAUDO I ;RAITERI R ;BONORA S ;SINICCO A ;DI GARBO A ;REYNOLDS HE ;HOGGARD PG ;BACK DJ ;DI PERRI G | |
| Cut-off values of ribavirin trough concentration for sustained virological response and for hematological toxicity in HCV/HIV-co-infected patients treated with RBV and Pegylated Interferon | 2007 | Aguilar Marucco D; Gonzalez de Requena D; Veronese L; Bonora S; Ibanez A; Baietto L; D'Avolio A; Sciandra M; Sinicco A; Di Perri G | |
| Cytokine network and acute primary HIV-1 infection. | 1993 | SINICCO A ;BIGLINO A ;SCIANDRA M ;FORNO B ;POLLONO AM ;RAITERI R ;GIOANNINI P | |
| Detection of stavudine concentrations in plasma of HIV-infected patients taking zidovudine | 2004 | BONORA S; BOFFITO M; D'AVOLIO A; SCIANDRA M; CACI AM; CONTA F; SINICCO A; DE ROSA FG; DI PERRI G | |
| EFFETTO DI LOPINAVIR/RITONAVIR SULLE CONCENTRAZIONI PLASMATICHE DI TRIGLICERIDI E COLESTEROLO: VALUTAZIONE FARMACOCINETICA | 2002 | Boffito M.; Bonora S.; Raiteri R.; Sinicco A.; Sciandra M.; D'Avolio A.; Sales P.; Trentini L.; Sciolè K.; Caci A.M.; Di Perri G. | |
| FARMACOCINETICA DEI FARMACI ANTIRETROVIRALI NELLA PRATICA CLINICA | 2002 | Boffito M.; Bonora S.; Raiteri R.; Sinicco A.; Sciandra M.; D'Avolio A.; Hoggard P.G.; Back D.J.; Di Perri G. | |
| GREATER IMMUNOLOGICAL RECOVERY ASSOCIATED WITH ADDITIONAL ENFUVIRTIDE IN THE TREATMENT OF NAIVE HIV-INFECTED PATIENTS AT VERY ADVANCED DISEASE STAGES: 24-WEEK RESULTS OF A RANDOMIZED, CONTROLLED, PILOT STUDY | 2009 | Calcagno A.; Bonora S.; Cometto C.; Fontana S.; Aguilar D.; D'Avolio A.; de Requena D. Gonzalez; Maiello A.; Sinicco A.; Di Perri G | |
| Immunoglobulin and Myc gene structure in lymphnode biopsies from HIV-positive patients with LAS and lymphoma. | 1990 | SAGLIO G ;FOÁ R ;GUERRASIO A ;DI CELLE PF ;PALESTRO G ;SINICCO A ;GOBBI M ;GAVOSTO F | |
| Impact of nevirapine (NVP) trough concentrations (Ctrough) on time to achieve and time maintenance of viral suppression (VS) in HIV+ patients taking NVP-based regimens | 2004 | Bonora S.; Requena D.; Garazzino S.; Sciandra M.; D'Avolio A.; Raiteri R.; Canta F.; Marrone R.; Boffito M.; Caci A.; Sinicco A.; Di Perri G. | |
| Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring. | 2003 | BOFFITO M; BACK DJ; HOGGARD PG; CACI A; S. BONORA; RAITERI R; SINICCO A; REYNOLDS HE; KHOO S; DI PERRI G | |
| Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boosting. | 2003 | BOFFITO M; BONORA S; SALES P; DAL CONTE I; SINICCO A; HOGGARD PG; KHOO S; BACK DJ; DI PERRI G | |
| Longitudinal analysis of the 90K glycoprotein in the Italian HIV-seroconversion study: temporal trend and predictability of the maturity of HIV infection. | 2004 | DORRUCCI M ;IACOBELLI S ;SULIGOI B ;PEZZOTTI P ;SINICCO A ;ANGARANO G ;TINARI N ;REZZA G | |
| Lopinavir protein binding in vivo through the 12-hour dosing interval | 2004 | BOFFITO M; HOGGARD PG; LINDUP WE; BONORA S; SINICCO A; KHOO SH; DI PERRI G; BACK DJ | |
| Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting | 2005 | GONZÁLEZ DE REQUENA D; BONORA S; GARAZZINO S; SCIANDRA M; D'AVOLIO A; RAITERI R; MARRONE R; BOFFITO M; DE ROSA FG; SINICCO A; DI PERRI G | |
| Oral lesions in children born to HIV-1 positive women. | 1993 | MONIACI D; CAVALLARI M; GRECO D; BRUATTO M; RAITERI R; PALOMBA E; TOVO PA; SINICCO A |